

Notice of Allowance received from US Patent Office for Use of the Cymerus™ MSCs in Asthma

Melbourne, Australia; 14 July 2022: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has today announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for a patent application covering the use of its proprietary Cymerus™ mesenchymal stem cell technology in treating asthma and allergic airways disease (AAD). The patent application entitled “Method for Treating Allergic Airways Disease (AAD)/Asthma” is wholly owned by Cynata. The inventors are Professor Chrishan Samuel, a Monash Biomedicine Discovery Fellow and Head of the Fibrosis Laboratory, and Dr Simon Royce, Research Fellow, Department of Pharmacology at Monash University.

The Notice of Allowance is sent to the applicant when the USPTO intends to issue a patent. The patent adds to the existing broad and comprehensive IP protection of the Cymerus manufacturing platform and its unique ability to yield highly consistent mesenchymal stem cells (MSCs) at scale, from a single donation, to create therapeutic stem cell products.

Dr Ross Macdonald, Cynata’s Chief Executive Officer, said:

“We are delighted that Professor Samuel’s investigations around the utility of Cynata’s proprietary MSCs in lung disease has resulted in yet a further patent, particularly in the commercially vital jurisdiction of the USA. This new milestone builds on our portfolio of wholly-Cynata owned patents and patent applications, providing further protection over our proprietary Cymerus technology to 2038 and beyond, particularly in the field of diseases of the lungs. The ability of the Cymerus platform to enable the production of consistent, high-quality mesenchymal stem cells at scale is a major competitive advantage and key to the ongoing development of off-the-shelf therapeutic stem cell products to target a range of devastating diseases worldwide”.

Cynata anticipates that the patent will be granted around October 2022, with an expiration date of 31 August 2038.

-ENDS-

Authorised for release by Dr Ross Macdonald, Managing Director & CEO

CONTACTS: Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119 343, ross.macdonald@cynata.com
Lauren Nowak, Media Contact, +61 (0)400 434 299, laurenmaree@live.com.au

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Planning for a Phase 2 clinical trial in GvHD under a cleared US FDA IND is presently underway. Clinical trials of Cymerus products in osteoarthritis (Phase



3), respiratory failure and diabetic foot ulcers (DFU) are currently ongoing. In addition, Cynata has demonstrated utility of its Cymerus technology in preclinical models of numerous diseases, including the clinical targets mentioned above, as well as critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.